Indivior (INDV) Earns “Buy” Rating from Jefferies Group

Jefferies Group reissued their buy rating on shares of Indivior (LON:INDV) in a research report sent to investors on Wednesday morning. They currently have a GBX 500 ($6.78) price target on the specialty pharmaceutical company’s stock.

Several other equities analysts have also recently commented on INDV. Royal Bank of Canada restated an outperform rating and issued a GBX 500 ($6.78) target price on shares of Indivior in a research report on Friday, December 1st. Morgan Stanley restated an equal weight rating and issued a GBX 410 ($5.56) target price on shares of Indivior in a research report on Friday, December 1st. Citigroup restated a neutral rating and issued a GBX 280 ($3.80) target price on shares of Indivior in a research report on Thursday, October 26th. Finally, Numis Securities restated a buy rating and issued a GBX 640 ($8.68) target price on shares of Indivior in a research report on Thursday, November 30th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of GBX 476.43 ($6.46).

Indivior (INDV) opened at GBX 401 ($5.44) on Wednesday. The company has a market cap of $2,890.00 and a P/E ratio of 1,542.31. Indivior has a 12-month low of GBX 246.50 ($3.34) and a 12-month high of GBX 421.50 ($5.72).

ILLEGAL ACTIVITY WARNING: “Indivior (INDV) Earns “Buy” Rating from Jefferies Group” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3148899/indivior-indv-earns-buy-rating-from-jefferies-group.html.

Indivior Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.